Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study

BACKGROUND: Rilpivirine is safe and effective in HIV-naïve patients with low baseline HIV-RNA or in switch strategy. It offers the advantages of few drug-drug interactions and a favourable toxicity profile. We aimed to determine the reasons for prescribing the rilpivirine (RPV)/tenofovir disoproxil...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMC Infect Dis
Egile Nagusiak: Sculier, Delphine, Gayet-Ageron, Angèle, Battegay, Manuel, Cavassini, Matthias, Fehr, Jan, Hirzel, Cedric, Schmid, Patrick, Bernasconi, Enos, Calmy, Alexandra
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2017
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5500925/
https://ncbi.nlm.nih.gov/pubmed/28683720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12879-017-2579-2
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak